Quebec City, Quebec, February 28, 2023 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering revolutionary solutions based on its proprietary optical technology, is pleased to announce the inaugural two SavvyWire live case broadcasts occurred on Monday, February 27, 2023, throughout the Cardiovascular Research Technologies (CRT) conference.
These initial live case broadcasts using the SavvyWire were performed and moderated by a panel of worldwide experts during a transcatheter aortic valve substitute procedure (TAVR) on the Medstar Washington Hospital Center by Toby Rogers, MD, PhD, and Lowell F. Satler, MD, FSCAI and through a balloon aortic valvuloplasty (BAV) at Tucson Medical Center by Thomas Waggoner, DO, FACC, FSCAI, FSVM, RPVI.
In response to Dr. Satler, “Having the ability to use SavvyWire during its first-ever live case broadcast demonstrates how CRT and the Medstar Washington Hospital Center are on the forefront of cardiovascular innovation. We expect SavvyWire to be a precious tool when treating patients with aortic stenosis and are encouraged about using it to enhance TAVR procedural efficiency.”
“We’re excited to have the chance to optimize aortic valve hemodynamics during BAV,” said Dr. Thomas Waggoner at Tucson Medical Center. “We imagine that SavvyWire has the potential to significantly improve procedural efficiency for these procedures via left ventricular pacing and continuous, accurate hemodynamics supporting our ability to know when the procedure is complete.”
“OpSens continues to execute a methodical launch plan for the SavvyWire,” said Louis Laflamme, President and CEO of OpSens. “While we’re still within the early stages of the launch cycle, the live cases at CRT are key events positioning OpSens for a full business launch within the U.S. in the approaching months. We imagine that SavvyWire has the potential to revolutionize the best way physicians treat patients with valvular disease.”
Cardiovascular Research Technologies (CRT) is a live, in-person annual educational interventional cardiology conference being held February 25-28, 2023, in Washington, D.C., with Dr. Ron Waksman because the course chairman. Attracting a worldwide audience from all seven continents, CRT 2023 has over 2,900 attendees, 20 live cases, and 12 late-breaking clinical trials.
SavvyWire is greater than a wire, because the world’s first and only sensor-guided TAVR solution. It uniquely provides a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement throughout the procedure, and reliable left ventricular pacing without the necessity for adjunct devices or venous access.
About OpSens Inc. (www.OpSens.com or www.OpSensmedical.com)
OpSens focuses mainly on cardiology. The Company offers a complicated optical-based pressure guidewire that goals at improving the clinical final result of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to supply the bottom drift within the industry and excellent lesions access. The OptoWire has been utilized in the diagnosis and treatment of greater than 200,000 patients in greater than 30 countries. It’s approved on the market in the USA, European Union, Japan, and Canada.
OpSens has recently received FDA clearance and Health Canada approval to commercialize the SavvyWire for transcatheter aortic valve substitute procedures (TAVR). This unique guidewire is a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement throughout the procedure, and reliable left ventricular pacing without the necessity for adjunct devices or venous access.
OpSens’ SavvyWire is on trend with a minimalist approach to TAVR and advances the procedure, allowing patients to depart the hospital earlier, sometimes the identical day.
The TAVR procedure is growing rapidly globally, driven by the aging population and up to date studies that exhibit its advantages for a broader array of patients. The worldwide TAVR market is currently estimated at over 200,000 procedures and is predicted to succeed in 400,000 in 2027.
OpSens can be involved in industrial activities in developing, manufacturing, and installing revolutionary fiber optic sensing solutions for critical applications.